Skip to Content

Banu Arun, MD

Present Title & Affiliation

Primary Appointment

Professor (Tenure), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor (Tenure), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1990 University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, MD

Postgraduate Training

1994-1997 Fellowship, Hematology and Oncology, Vincent T. Lombardi Cancer Center Georgetown University, Washington, DC
1990-1994 Residency, Internal Medicine, University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey


Academic Appointments

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2004-8/2010
Associate Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2004-8/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642, 2013. PMID: 23370825.
2. Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI, Arun B, Parmigiani G. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571-579, 2013. PMID: 23690142.
3. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-17, 2013. PMID: 23337751.
4. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347-55, 2012. PMID: 22270937.
5. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012. PMID: 22622473.
6. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J 18(3):261-6, 2012. PMID: 22583196.
7. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. PMID: 21761402.
8. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blind, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res 5(9):1144-1154, 2012. PMID: 22827973.
9. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res 5(2):276-82, 2012. PMID: 22102688.
10. Ready K, Arun B, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 12/2011. e-Pub 6/2011. PMID: 21681553.
11. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun BK. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-212, 2011.
12. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-3907, 2011. PMID: 21365619.
13. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. PMID: 21830012.
14. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemorherapy with or withough G-CSF in locally advanced breast cancer: Long-term results. Oncologist 16(11):1527-34, 2011. PMCID: PMC3233286.
15. Bayraktar S, Elsayegh N, Gutierrez-Barerra AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstram F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2011. PMID: 22009639.
16. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 12(5):496-503, 2011. PMID: 21441069.
17. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: a single institution experience. J Clin Oncol 28(29):3739-3746, 2011. PMID: 21900106.
18. Euhus DM, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt KK, Xia W, O'Shaughnessy JA, Grant M, Arun B, Dooley W, Miller A, Flockhart DA, Lewis C. Tamoxifen downregulates Ets-oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction. Cancer Prev Res 4(11):1852-1862, 2011. PMID: 21778330.
19. Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw 8(10):1148-55, 11/2010. PMID: 20971839.
20. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010. PMID: 20054647.
21. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. A phase II trial of anastrozole plus goserelin in the treatment of hormone receptor positive, metastatic carcinoma of the breast in pre-menopausal women. J Clin Oncol 28(25):3917-3921, 2010. PMID: 20679610.
22. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun B, Letrent S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor canertinib (CI-1033) in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64(6):1139-1148, 2010.
23. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: Large and small trials. Semin Oncol 37(4):367-383, 2010. PMID: 20816507.
24. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: A multi-center case-only analysis. Breast Cancer Res Treat 124(2):441-51, 2010. PMCID: PMC2925060.
25. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-20, 2010. PMID: 20733129.
26. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-S-transferase-pi expression in early breast cancer: Association with outcome and response to chemotherapy. Cancer Invest 28(5):554-559, 2010. PMID: 20210524.
27. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244, 2010. PMID: 20609467.
28. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-1187, 2010. PMID: 20423989.
29. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115(4):725-730, 2009. PMID: 19127556.
30. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258, 2009.
31. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of pre-invasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2(2):122-7, 2009. PMID: 19174581.
32. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A, Hortobagyi G, Arun B. Clinical and pathological characteristics of patients with BRCA-positive and BRCA-negative breast cancer. JCO 26(26):4282-8, 2008. PMID: 18779615.
33. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. PMID: 18303485.
34. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2008. PMID: 18581139.
35. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun B, Hortobagyi GN. Ductal Carcinoma In Situ: State of the Science and Roadmap to Advance the Field. J Clin Oncol 27(2):279-88, 2008. PMID: 19064970.
36. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-7, 2008. PMID: 18373644.
37. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun B, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 2008. PMID: 18515258.
38. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID: 18776816.
39. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Hortobagyi G, Valero V. Phase III study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. PMID: 18300256.
40. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007.
41. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-48, 2007. PMID: 17699874.
42. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2007. PMID: 18026834.
43. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. PMID: 17676585.
44. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(14 Pt 1):4274-82, 2006. PMID: 16857802.
45. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745-51, 2006. PMID: 17109443.
46. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14(7):1681-5, 2005. PMID: 16030101.
47. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005. PMID: 15738535.
48. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. PMID: 15136595.
49. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. PMID: 12972520.

Grant & Contract Support

Title: A novel approach to treatment of BRCA mutation positive breast cancer
Funding Source: NIH/NCI
Role: Multi-Principal Investigator (Clinical)
Principal Investigator: Ozpolat
Duration: 4/1/2015 - 3/31/2017
Title: Prevention and early intervention of ER-breast cancer by blocking PI3K/AKT activation in combination with metabolic modulation
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Yu
Duration: 3/1/2015 - 2/28/2018
Title: A model for individualized risk prediction of contralateral breast cancer
Funding Source: The University of Texas at Dallas
Role: Co-Investigator
Principal Investigator: Biswas
Duration: 9/1/2014 - 8/31/2016
Title: Increasing genetics services availability to underserved high risk breast cancer patients
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 4/1/2014 - 3/31/2015
Title: Genetic risk prediction in primary care
Funding Source: The University of Texas at Dallas
Role: Multi Principal Investigator (Clinical)
Principal Investigator: Co-PI Biswas
Duration: 1/1/2013 - 12/31/2015
Title: Cancer prevention agent development program: Early phase clinical research consortium
Funding Source: NIH/NCI
Role: Co-Investigator and Member of the Executive Committee
Principal Investigator: Brown
Duration: 9/24/2012 - 9/23/2017
Title: Advancing compliance in breast cancer risk-reduction strategies for underserved women identified with hereditary cancer syndromes
Funding Source: Avon Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 1/31/2015
Title: Adolescent's long-term adaption to familial cancer risks
Funding Source: Georgetown University
Role: Co-Investigator
Duration: 12/1/2010 - 11/30/2014
Title: Zyflamend and breast health: MDACC
Funding Source: New Chapter Inc.
Role: Principal Investigator
Duration: 6/1/2010 - 9/30/2014
Title: Yoga for women with breast cancer undergoing radiotherapy
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 4/1/2010 - 3/31/2016
Title: Development of novel early detection and prevention strategies for ER negative breast cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Principal Investigator (Clinical)
Duration: 9/25/2009 - 9/24/2015
Title: UT MD Anderson Cancer Center CCOP Research Base
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 4/10/2007 - 3/31/2015
Title: NIH-Phase I and II clinical trials of chemopreventive agents
Funding Source: NIH/NCI
Role: Co-Investigator (Clinical)
Duration: 9/30/2003 - 9/29/2014

Last updated: 2/4/2015